论文部分内容阅读
主要临床研究均证实干扰素-β(IFN-β)治疗复发-缓解型多发性硬化(RRMS)疗效肯定,且在一定剂量范围内疗效与剂量、频次呈正相关,IFN-β已经成为治疗RRMS的首选药物之一。IFN-β常见副作用包括流感样症状和注射部位反应等,在应用IFN-β早期尤为明显;大多数副作用比较轻微,严重的或患者不能耐受的不良反应少见。IFN-β中和抗体阳性可能影响疗效,但尚无统一结论。此文就不同类型IFN-β的异同及其治疗MS疗效判定标准、治疗时机和治疗剂量等作一综述。
The main clinical studies have confirmed the positive effect of interferon-β (IFN-β) treatment of relapsing-remitting multiple sclerosis (RRMS), and in a certain dose range of efficacy and dose, frequency was positively correlated, IFN-β has become RRMS One of the preferred drugs. Common side effects of IFN-β, including flu-like symptoms and injection site reactions, especially in the early application of IFN-β early; most minor side effects, serious or patients can not tolerate adverse reactions rare. Positive IFN-β neutralizing antibody may affect the efficacy, but there is no unanimous conclusion. This article reviews the similarities and differences of different types of IFN-β and the criteria for determining the therapeutic effect of MS, timing of treatment and therapeutic dose.